Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy Arsenal
The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Steven Katz, MD, on Assessing New Delivery Methods for CAR T-Cell Therapy
The chief medical officer of Trisalus Life Sciences discussed studies evaluating the company’s PEDD system.
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR Platform
The vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.
Frank Borriello, MD, PhD, on Next Steps for SUPLEXA-101 for Solid Tumors
The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed progress of the phase 1 trial and possible future evaluations of the therapy.
Alexandra Lisi on Scaling Manufacturing Efficiency to Support Cell Therapy
The cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.
Mustafa Turkoz, PhD, on Rejuvenating Immune Cells With ERA Reprogramming
The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.
Raphaël Ognar on Developing CIR-NK Cells to Better Target Cancer Cells
The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.
Steven Katz, MD, on Tackling TME Immunosuppression, Intratumoral Pressure
The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.
Levi Gray-Rupp, PhD, on Using Integrated Circuit T-Cells Against Solid Tumors
The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.
Dan Shelly, PhD, on Advantages of Multi-Targeted OmniCAR Platform
The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.
Frank Borriello, MD, PhD, on Promising Activity of SUPLEXA-101 Across Cancers
The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.
Rachel Lynn, PhD, on Reprogramming Cell Therapies to Combat Exhaustion
The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.
